ATE413189T1 - Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 - Google Patents

Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1

Info

Publication number
ATE413189T1
ATE413189T1 AT98934401T AT98934401T ATE413189T1 AT E413189 T1 ATE413189 T1 AT E413189T1 AT 98934401 T AT98934401 T AT 98934401T AT 98934401 T AT98934401 T AT 98934401T AT E413189 T1 ATE413189 T1 AT E413189T1
Authority
AT
Austria
Prior art keywords
amino acids
epitope
hiv
compositions
sequence
Prior art date
Application number
AT98934401T
Other languages
English (en)
Inventor
Gideon Goldstein
Original Assignee
Thymon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thymon Llc filed Critical Thymon Llc
Application granted granted Critical
Publication of ATE413189T1 publication Critical patent/ATE413189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT98934401T 1997-07-11 1998-07-10 Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 ATE413189T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/893,853 US5891994A (en) 1997-07-11 1997-07-11 Methods and compositions for impairing multiplication of HIV-1

Publications (1)

Publication Number Publication Date
ATE413189T1 true ATE413189T1 (de) 2008-11-15

Family

ID=25402225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934401T ATE413189T1 (de) 1997-07-11 1998-07-10 Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1

Country Status (9)

Country Link
US (6) US5891994A (de)
EP (1) EP0994724B1 (de)
JP (1) JP4278293B2 (de)
AT (1) ATE413189T1 (de)
AU (1) AU745012C (de)
CA (1) CA2295691C (de)
DE (1) DE69840195D1 (de)
ES (1) ES2317668T3 (de)
WO (1) WO1999002185A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG71046A1 (en) * 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20010008627A1 (en) * 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
WO2000078969A1 (en) * 1999-06-21 2000-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv tat peptides and multiple peptide conjugate system
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
WO2003015702A2 (en) * 2001-08-16 2003-02-27 The General Hospital Corporation Epitopes of human immunodeficiency virus-1
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
WO2003091275A2 (en) * 2002-04-23 2003-11-06 Andrea Savarino Compositions containing anti-hiv peptides and methods of use
US20060104988A1 (en) * 2002-12-18 2006-05-18 Pauza C D Vaccines against hiv-1 tat protein to generate neutralizing antibodies
US7482016B2 (en) * 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
WO2005062871A2 (en) * 2003-12-19 2005-07-14 University Of Maryland Biotechnology Institute Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
US20060205070A1 (en) * 2004-01-13 2006-09-14 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services HIV TEV compositions and methods of use
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
CA2597373A1 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
US20080280305A1 (en) * 2005-02-15 2008-11-13 Thymon, Llc Assays for Detecting Hiv-1 Tat Protein in Hiv-1 Infection
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US8460697B2 (en) * 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US20110027315A1 (en) * 2007-09-07 2011-02-03 Allen Harmsen Protein cages and their uses
EP3128010A1 (de) 2007-11-28 2017-02-08 The Trustees Of The University Of Pennsylvania Simian-adenoviren sadv-30 der unterfamilie e und verwendungen davon
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
EP2325298B1 (de) 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania AFFENADENOVIREN SAdV-36, -42.1, -42.2, AND -44 UND DEREN NUTZUNG
ES2552688T3 (es) 2008-10-31 2015-12-01 The Trustees Of The University Of Pennsylvania Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
MX358019B (es) 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
ES2748423T3 (es) 2012-12-06 2020-03-16 Pin Pharma Inc Tratamiento de trastornos inflamatorios, autoinmunitarios y neurodegenerativos con polipéptidos derivados de Tat inmunosupresores
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
CN119072330A (zh) 2022-03-14 2024-12-03 世代生物公司 异源初免加强疫苗组合物和使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4531167A (en) * 1983-08-25 1985-07-23 Pioneer Research, Inc. Servowriter system for magnetic disc drives
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US7815916B1 (en) * 1984-08-22 2010-10-19 The United States Of America As Represented By The Secretary Of Health And Human Services Cloning and expression of HTLV-III DNA
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5801056A (en) * 1985-05-24 1998-09-01 Dana-Farber Cancer Institute Nucleic acid encoding HIV-1 tat protein
US4735896A (en) * 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
PT83682B (en) * 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
CS256960B1 (en) * 1985-11-16 1988-04-15 Viktor Krchnak Peptides with properties of antigenic determinants and method of their production
US4812929A (en) * 1985-11-19 1989-03-14 Rodime Plc Head positioning mechanism for rotating disk data storage system
US4839288A (en) * 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5306614A (en) * 1986-01-22 1994-04-26 Institut Pasteur Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2)
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030714A (en) * 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
US5476765A (en) * 1987-01-09 1995-12-19 United Biomedical, Inc. Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
US4888290A (en) * 1987-11-06 1989-12-19 Coulter Corporation Monoclonal antibody specific to HIV antigens
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
GB8808892D0 (en) * 1988-04-15 1988-05-18 British Bio Technology Gene synthesis
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
ATE142266T1 (de) * 1989-12-21 1996-09-15 Whitehead Biomedical Inst Verfahren zum transport von molekülen in eukaryotenzellen
CA2074188C (en) * 1990-01-18 2004-05-11 Julianna Lisziewicz Vector with multiple tat activation response elements affecting gene expression
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
ATE146483T1 (de) * 1990-10-24 1997-01-15 Allelix Biopharma Peptidische hemmer der hiv-replikation
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
JPH06508603A (ja) * 1991-02-14 1994-09-29 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション ＨＩＶ　Ｔａｔタンパク質に対する新規インテグリン特異性
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
WO1993024632A1 (en) * 1992-05-22 1993-12-09 Dana Farber Cancer Institute Hybrid siv/hiv-1 viral vectors and monkey model for aids
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5421412A (en) * 1994-03-10 1995-06-06 North Carolina State University Methods and compositions for fracturing subterranean formations
AU2638295A (en) * 1994-05-23 1995-12-18 Gideon Goldstein Compositions of transactivating proteins of human immunodeficiency virus
US5793559A (en) * 1996-02-27 1998-08-11 Quantum Corporation In drive correction of servo pattern errors
SG52990A1 (en) * 1996-07-09 1998-09-28 Ibm Improvements to radial self-propagation pattern generation for disk file servowriting
US5875064A (en) * 1996-07-09 1999-02-23 International Business Machines Corporation Method and system for accurate self-servowriting with normalization in a disk drive
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6023145A (en) * 1999-04-21 2000-02-08 Guzik Technical Enterprises Head and disk tester with a thermal drift-compensated closed-loop positioning system
US6507450B1 (en) * 1999-06-11 2003-01-14 Western Digital Technologies, Inc. Method of continuously recording servo bursts along one continuous, single helix spiral
US6519107B1 (en) * 1999-09-24 2003-02-11 Maxtor Corporation Hard disk drive having self-written servo burst patterns
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CA2597373A1 (en) * 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1

Also Published As

Publication number Publication date
JP2001509368A (ja) 2001-07-24
ES2317668T3 (es) 2009-04-16
US7008622B2 (en) 2006-03-07
EP0994724B1 (de) 2008-11-05
AU745012B2 (en) 2002-03-07
JP4278293B2 (ja) 2009-06-10
EP0994724A1 (de) 2000-04-26
US6525179B1 (en) 2003-02-25
AU745012C (en) 2003-08-07
US5891994A (en) 1999-04-06
WO1999002185A1 (en) 1999-01-21
US20060258594A1 (en) 2006-11-16
AU8392798A (en) 1999-02-08
CA2295691C (en) 2012-01-24
US20030194408A1 (en) 2003-10-16
US6193981B1 (en) 2001-02-27
CA2295691A1 (en) 1999-01-21
US20030166832A1 (en) 2003-09-04
EP0994724A4 (de) 2004-12-08
DE69840195D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
ATE413189T1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
DE69331832D1 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DK601786A (da) Hidtil ukendte prokoagulationsproteiner
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
BR9814276A (pt) Antìgenos de superfìcie
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
TW469273B (en) Bone stimulating factor
DK0426314T3 (da) HIV-relaterede peptider
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
ES2023746A6 (es) Procedimiento de preparacion de peptidos de serina-acido aspartico- lisina
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties